Authors
Latest:
Komrokji on the Classification of MDSRami Komrokji, MD, discusses the different systems of classifying myelodysplastic syndrome.
Latest:
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid CancerDadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.
Latest:
Differing Trial Designs for Immunotherapy in MIBC Yield Favorable OutcomesRana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.
Latest:
Dr. Randal S. Weber on Anti-EGFR Agents Showing Efficacy in Squamous Cell CarcinomaWeber says overactivity of these EGFR receptors may cause SCC tumors to become more aggressive. He adds that in a recent, small-scale study, effectively blocking the EGFR receptor in the tumor with anti-EGFR therapy proved to be successful.
Latest:
Stool DNA Test for Colon CancerRandall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses the benefits and challenges associated with stool DNA test for colon cancer.
Latest:
FDA Advances the Use of Metastasis-Free Survival as an Endpoint in nmCRPCIn November 2018, the FDA issued a draft guidance recommending metastasis-free survival as an endpoint in drug trials for nonmetastatic castration-resistant prostate cancer, suggesting a major change in expectations for treatment of this tumor type.
Latest:
The Best Therapy Option for a Patient With mCRPCRaoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.
Latest:
Assessing the Role of Darolutamide in CRPCRaoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses takeaways from the ARAMIS study of darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
Latest:
The Role of FLT3 Inhibitors in Acute Myeloid LeukemiaRaoul Tibes, MD, PhD, physician-scientist at the University Hospital Head Myeloid Malignancies, Department of Internal Medicine II at the University Hospital in Würzburg, and adjunct consultant at Mayo Clinic, discusses the role of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.
Latest:
Dr. Raquell Reinbolt On Further Studies Into Women's Lifestyles With Breast CancerRaquell Reinbolt, MD, assistant professor, Internal Medicine at Ohio State University College of Medicine, talks about potential further studies into the lifestyles of women with breast cancer.
Latest:
Tucatinib Combination Improved Survival in HER2+ Breast CancerRashmi K. Murthy, MD, discusses the pivotal HER2CLIMB trial, which evaluated the addition of tucatinib to trastuzumab plus capecitabine in patients with HER2-positive metastatic breast cancer.
Latest:
EGFR Tyrosine Kinase Inhibitors and SCLC TransformationRavi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.
Latest:
Choosing Therapy for NSCLC to SCLC Transformation in EGFR+ DiseaseRavi Salgia, MD, PhD, discusses how to address and treat transformation from non–small cell lung cancer to small cell lung cancer.
Latest:
Monoclonal Antibodies for the Treatment of Patients With Multiple MyelomaRavi Vij, MD, associate professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, discusses the monoclonal antibody daratumumab for the treatment of patients with heavily pretreated multiple myeloma.
Latest:
The Significance of Surgery Quality in NSCLCRaymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).
Latest:
Investigating Immunotherapy Versus Best Supportive Care in Patients With CRCRaymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.
Latest:
Dr. Rebecca Feldman on Caveolin-1 and its Potential in Breast Cancer TreatmentRebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.
Latest:
The Clinical Activity of Rucaparib in Patients With Ovarian CancerRebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the clinical activity and efficacy of rucaparib in patients with high-grade ovarian carcinoma and a BRCA mutation during an interview at the 2016 ESMO Congress.
Latest:
Poor Survival Rates Spur Research in Immunotherapy Combinations, PARP Inhibitors in SCLCDespite advances in small cell lung cancer, overall 5-year survival remains at 5% to 10%. At the time of presentation, approximately 30% of patients with SCLC have limited stage disease, which is confined to the mediastinum, the hemithorax, or the supraclavicular lymph nodes. The remaining patients, who have extensive-stage SCLC, have tumors beyond the supraclavicular areas.
Latest:
The Need for Novel Therapies in Mantle Cell LymphomaRekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the need to develop novel therapies in mantle cell lymphoma, including a study that explored the synergistic activity of p97 inhibitors with histone deacetylase 6 inhibitors.
Latest:
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC​Renato G. Martins, MD, MPH, discusses why nivolumab is not ready to move up to being a firstline treatment in non
Latest:
The Outlook for CAR-Modified T CellsRenier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Latest:
Management of Hepatocellular CancerHepatocellular cancer (HCC) is a rapidly fatal malignancy that is often diagnosed at an advanced stage when it is not curable. Despite a rise in incidence, this cancer is not as common in the Western world as it is in Asia and Africa.
Latest:
Identifying Gaps Between HCPs and Patients in HER2-Positive Breast Cancer TreatmentIn an interview with Targeted Oncology, Reshma Mahtani, DO, discussed data from a quality improvement initiative identifying issues for health care professionals and patients with HER2-positive breast cancer.
Latest:
Dr. Reuben S. Harris on APOBEC3B as a Possible Treatment Variable in Breast CancerAPOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Latest:
Dr. Rex Chin-Wei Yung on the Role of Pulmonology in OncologyRex Chin-Wei Yung, MD, FCCP, discusses the value of teamwork in oncology, specifically lung cancer, and the importance of pulmonologists.
Latest:
Key Components to Successfully Integrating LI-RADS in CentersRiccardo Lencioni, MD, discusses how to successfully integrate Liver Imaging Reporting and Data Systems their clinical practice.<br />
